上海药明巨诺生物科技有限公司 JW Therapeutics Mediaroom

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative...

2025-10-31 17:38 2403

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative ...

2025-06-05 09:04 3575

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative...

2025-01-10 17:00 6579

$JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma$

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovativ...

2024-08-27 17:00 5128

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Thera...

2024-05-30 18:10 4647

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative ...

2024-01-04 21:40 4254

JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biot...

2024-01-02 20:15 4056

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

SHANGHAI, April 10, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-04-10 19:30 4579

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-03-30 08:00 3846

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

SHANGHAI, March 8, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-03-08 17:30 4346

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2023-02-28 17:30 3728

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2022-12-12 18:00 5583

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

SHANGHAI, Nov. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ...

2022-11-09 17:00 4965

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

* Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors inChina...

2022-10-27 07:53 5038

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2022-10-10 20:00 4210

Latest News